Smarter RWE for growing Biotechs.
CHEORS powered by BioBridges delivers real-world evidence solutions tailored for small to mid-sized biotech companies—backed by expert reviews, clinical insights, and deep data experience.
Achieving your goals without overextending your teams.
We help your growing biotech generate cost-effective, strategic RWE outputs that support regulatory, clinical, and commercial goals—without overextending your internal teams.
Delivering credible, customized publications.
From abstracts to manuscripts, CHEORS transforms real-world data into credible, customized publications aligned with your company’s stage and strategy.
Offering a scalable, low-risk service model.
Our scalable, low-risk service model allows your growing biotech to access expert-driven RWE solutions without committing to large contracts.
The CHEORS Difference
Broad experience across many therapeutic areas.
- We’ve been an RWE partner for a long time, contributing to 150+ studies across 30+ unique data sources—giving us a broad, credible foundation across therapeutic areas.
Quality you can count on for every project.
- Every project includes two expert reviewers, doubling the accuracy and quality without the cost.
- Our network of doctoral-level subject matter experts in RWE gives our publications an added level of depth.
When should Biotech startups invest in RWE?
So, when is the right time to make the leap? The answer is often earlier than you think. Your Biotech startup can benefit tremendously from integrating HEOR and RWE as early as the preclinical phase, all the way through phase three.
About CHEORS
We deliver fully integrated HEOR / RWD / RWE solutions with cutting-edge methodology, technology, and professional expertise. With our complete HEOR solutions, we effectively quantify and communicate the clinical and economic value of your products.
Talk to us.
Want to learn more about real-world evidence solutions for your emerging Biotech? Schedule a call with one of our team members.